Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Yamazaki

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Translational Lung Cancer Research|February 9, 2026
Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratioSoichiro Minami, Yusuke Yamazaki, Shin Saito, et al.
Cancer Reports (Hoboken, N.J.)|July 25, 2024
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release SyndromeSoichiro Minami, Yosuke Kawashima, Yasuhiko Munakata, et al.
Translational Lung Cancer Research|October 24, 2025
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancerSoichiro Minami, Tsuyoshi Doman, Yukihiro Toi, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Translational Lung Cancer Research|February 9, 2026
Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratioSoichiro Minami, Yusuke Yamazaki, Shin Saito, et al.
Cancer Reports (Hoboken, N.J.)|July 25, 2024
Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release SyndromeSoichiro Minami, Yosuke Kawashima, Yasuhiko Munakata, et al.
Translational Lung Cancer Research|October 24, 2025
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancerSoichiro Minami, Tsuyoshi Doman, Yukihiro Toi, et al.
Pageof 3